DC Business DC

FDA points to deficiencies in Vanda's latest drug application

Washington Business Journal

Jul 22, 2019

Vanda Pharmaceuticals Inc. disclosed a note from federal regulators that pointed to deficiencies in its latest application for approval for a jet lag disorder treatment - but said…

Read the full story at Washington Business Journal

Topics

#Biotech

FDA points to deficiencies in Vanda's latest drug application

Topics

More from DC Business

Shilling Canning files for bankruptcy protection amid rent struggles

Steve Case's Revolution teams with Hilton to deliver luxury Costa Rican resort 19 years in the making

Challenge to ACA preventive-care panel draws skepticism from Supreme Court

Can Trump remove Powell as Fed chair before his term ends?

Amazon closing one of its Northern Virginia supermarkets

International travelers give D.C.'s hospitality business only slight boost

Drone firm announces Virginia expansion and college partnership

Mixed-use development in downtown Bethesda looks to add more retail, residences